Financial Data and Key Metrics Changes - Consolidated revenue for Q4 2025 was $267.7 million, representing a 7.9% increase year-over-year [4][21] - Adjusted EBITDA for Q4 was $63.8 million, an 18.6% increase from the previous year, with an adjusted EBITDA margin of 23.8% [4][25] - Full-year consolidated revenues reached $1.023 billion, up 7.8% compared to 2024, with adjusted EBITDA of $230.2 million, a 14.6% increase [20][21] Business Line Data and Key Metrics Changes - The company completed 1.4 million advanced imaging exams in Q4, a 7.7% increase year-over-year [4] - Professional fee revenues for Q4 were $66.8 million, reflecting a growth of 10.6% [23][25] - Management fee and other revenues totaled $57.2 million, consisting of management fees from health system joint ventures and pass-through revenues [23][24] Market Data and Key Metrics Changes - System-wide revenue growth was 10.6% in Q4, driven by increased procedure volumes and a shift towards advanced imaging [21][23] - Advanced imaging modalities, including MRI, CT, and PET, are expected to continue driving higher revenue per procedure and margins [6][30] Company Strategy and Development Direction - The company aims to drive same-center growth, geographic expansion, and strategic service line expansion as key strategic initiatives for 2026 [9][12] - Plans to open 8-10 new de novo centers annually, with a focus on joint ventures to align with health system priorities [12][13] - The introduction of new service lines, such as Breast Arterial Calcification screenings, is part of the strategy to enhance service offerings and drive growth [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to capitalize on growth opportunities, citing strong execution and a favorable operating environment [8][18] - The company anticipates continued growth in advanced imaging, with expectations for revenue in 2026 to be between $1.045 billion and $1.097 billion [29][30] - Management noted that Q1 is typically the lowest for revenue and adjusted EBITDA, but they expect to recover lost volumes throughout the year [32][70] Other Important Information - The company completed a small tuck-in acquisition in North Carolina and is continuously evaluating accretive M&A opportunities [14][15] - The balance sheet was strengthened with $58.8 million in cash and cash equivalents at the end of Q4, compared to $26.1 million at the end of 2024 [26][27] Q&A Session Summary Question: Growth in advanced imaging versus routine imaging for 2026 - Management confirmed a focus on advanced imaging growth, which is expected to outpace routine imaging growth, with a strong pipeline of new center openings [37][40] Question: Cash flow and CapEx expectations for 2026 - Management indicated strong cash generation capabilities and emphasized that CapEx will primarily focus on de novo openings and equipment upgrades [43][46] Question: Rate growth expectations for 2026 - Management expects rate growth to be driven by volume increases in advanced modalities and modest increases in contracted rates with payers [51][53] Question: Strategies to increase patient referrals - The company has a robust engagement strategy with referring physicians, focusing on high-referring specialties and targeted marketing campaigns [63][64] Question: Impact of weather and macro conditions on volumes - Management acknowledged the impact of weather on Q1 volumes but expressed confidence in recovering lost volumes and maintaining full-year guidance [70][72]

Core Viewpoint - Ultrasound examination is a non-invasive, radiation-free imaging technique that utilizes the reflection and refraction properties of ultrasound waves to provide real-time images of internal body structures, making it an essential tool in clinical diagnosis [1][2]. Group 1: Advantages of Ultrasound - Ultrasound has several significant advantages over CT and MRI, including being non-invasive and radiation-free, making it suitable for pregnant women, infants, and patients with weakened constitutions [2][3]. - It provides real-time dynamic imaging, capturing organ movements such as heartbeats and gastrointestinal motility, which enriches diagnostic information [2][3]. - The examination is quick and convenient, often requiring no special preparation, and can produce immediate diagnostic reports, which is crucial for emergency situations [2][3]. - Ultrasound is relatively low-cost, effectively reducing the financial burden on patients [2][3]. Group 2: Applications of Ultrasound - Ultrasound is widely used in various clinical fields, including abdominal ultrasound for screening liver, gallbladder, pancreas, spleen, kidneys, and bladder diseases, allowing for quick detection of conditions like fatty liver and gallstones [3][4]. - Cardiovascular ultrasound is vital for assessing heart and vascular health, helping to identify congenital heart diseases, myocardial diseases, and heart failure, and is essential for early detection of carotid artery diseases [3][4]. - In obstetrics, ultrasound monitors fetal development, assesses placental and amniotic fluid conditions, and screens for congenital abnormalities, ensuring maternal and fetal health [4]. - Ultrasound is also applied in thyroid, breast, and musculoskeletal assessments, aiding in the early detection of nodules and injuries [4]. Group 3: Common Misconceptions - There are misconceptions regarding ultrasound's capabilities, such as the belief that it can detect all diseases, which is not true as its effectiveness varies by examination site and type of lesion [5][6]. - Many patients mistakenly equate the presence of nodules in ultrasound reports with cancer, while most nodules are benign and require careful evaluation by clinicians [6][7]. - A common myth is that ultrasound involves radiation, which is incorrect; it is safe for sensitive populations like pregnant women and infants [6][7]. - Preparation for ultrasound varies by type, and failing to follow preparation guidelines can affect image quality and diagnostic accuracy [7]. - Ultrasound reports should not be the sole basis for treatment decisions; they serve as diagnostic references that need to be interpreted in conjunction with clinical evaluations [7]. Group 4: Role of Ultrasound Professionals - Ultrasound professionals play a crucial role in healthcare, ensuring the accuracy and reliability of ultrasound examinations through their expertise and attention to detail [8][9]. - They communicate effectively with patients to alleviate anxiety and provide clear explanations of findings, contributing to informed decision-making in patient care [8][9]. - Continuous advancements in ultrasound technology are expected to enhance its role in disease diagnosis, treatment monitoring, and health management, providing stronger health safeguards for the public [9].

Core Viewpoint - Breast cancer is the most common malignant tumor among women globally, with an increasing incidence rate, approximately 2.3 million new cases reported annually according to the World Health Organization [1] Group 1: Incidence and Demographics - The incidence of breast cancer is rising both globally and in China, with a notable increase in younger patients [3] - Breast cancer typically occurs more frequently in women around the ages of 55 to 60, with a secondary peak in women around 40 years old [3] - Younger breast cancer patients tend to experience faster disease progression and a higher likelihood of lymph node metastasis [3] Group 2: Symptoms and Self-Examination - The primary symptom of breast cancer is a breast lump, with about 80% of patients presenting with this symptom at diagnosis [5] - Most early-stage breast cancer patients do not exhibit obvious symptoms, making regular self-examination crucial [5] - Recommended self-examination frequency is once every one to two months, including visual checks for skin changes and nipple discharge [7] Group 3: Screening and Diagnosis - Due to the uncertainty of self-examinations, regular hospital screenings are essential, including ultrasound, mammography, MRI, and ductoscopy [9] - Early-stage breast cancer often presents with calcifications that are difficult to detect via ultrasound, necessitating mammography for accurate diagnosis [9] - It is advised that women over 40 undergo mammography screenings every one to two years, especially if abnormalities are detected on X-rays [11]

Core Viewpoint - Breast cancer is a significant health threat to women in China, with a rising incidence rate, necessitating earlier screening for high-risk individuals [1][2][3] Group 1: Breast Cancer Statistics and Risk Factors - In 2022, there were 357,200 new breast cancer cases in China, accounting for 15.6% of all new cancer cases [1] - Family history, particularly if a direct relative was diagnosed with breast cancer before the age of 50, significantly increases individual risk and warrants earlier screening [1][2] Group 2: Screening Recommendations - For women under 40, especially those with high-risk factors (e.g., family history, breast hyperplasia), ultrasound is recommended due to its safety and accessibility [2] - Women over 40 should consider a combined screening approach using mammography and ultrasound to improve detection rates, particularly for microcalcifications [2] - High-risk individuals should undergo personalized management based on specific risk factors, including reproductive history and lifestyle choices [2] Group 3: Importance of Early Detection - Early detection can lead to a nearly 90% five-year survival rate for breast cancer, compared to less than 30% for late-stage diagnoses [3] - Young women should not ignore symptoms such as breast lumps or unusual skin changes, as early intervention is crucial regardless of age [3]

Core Viewpoint - Breast cancer is a significant health threat to women in China, but advancements in medical treatment have improved the 5-year survival rate to 83.2% [1] Group 1: Current Situation and Statistics - Approximately 72% of breast cancer patients in China are diagnosed at an early stage, yet 30% of high-risk patients may experience recurrence within the first few years [1] - The 5-year survival rate for late-stage breast cancer is only 20%, with a median survival time of 2-3 years [1] Group 2: Genetic Factors and Risk Assessment - 5%-10% of breast cancer patients have hereditary breast cancer due to genetic mutations, with BRCA1/2 being the most critical susceptibility genes [2] - 5%-20% of breast cancer patients in China carry BRCA mutations, which are more common in HER2-negative breast cancer, particularly in triple-negative breast cancer (TNBC) [2] Group 3: Importance of Genetic Testing - Genetic testing for BRCA1/2 is recommended for patients with a family history of breast cancer and those diagnosed with invasive TNBC, especially with lymph node involvement [3] - Accurate diagnosis through genetic testing is essential for developing personalized treatment plans and improving treatment efficacy [3] Group 4: Treatment and Prevention Strategies - New treatment options based on genetic mutations require clear identification of the mutation-carrying population for effective outcomes [4] - Regular breast cancer screenings are advised for women aged 35 to 70, along with self-examinations to facilitate early detection and treatment [4]

Core Viewpoint - Guangdong Province's Medical Insurance Bureau has announced the optimization and integration of medical service pricing for dialysis, ultrasound, and traditional Chinese medicine, ensuring that the financial burden on dialysis patients does not increase [1][2]. Group 1: Dialysis Service Pricing - The previous 32 items related to "machine-assisted plasma exchange" have been consolidated into 21 items under "blood dialysis fees," with a provincial maximum price set at 390 yuan per session, covering all necessary procedures and resources [2]. - The maximum price for peritoneal dialysis (manual) is set at 45 yuan per session, while automated peritoneal dialysis is priced at 16 yuan per hour [2]. - Public medical institutions must charge according to the integrated pricing for dialysis services and cannot charge separately for different components of the service [2][3]. Group 2: Traditional Chinese Medicine and Ultrasound Pricing - The previous 60 items for "ordinary acupuncture" have been consolidated into 10 pricing items for acupuncture methods, while 105 items for "fracture manual reduction" have been reduced to 9 items for orthopedic methods [4]. - The pricing for ultrasound services has been streamlined from 84 items to 13, with ultrasound report services now included in the ultrasound pricing, eliminating separate charges for reports [4]. - The maximum prices for the newly integrated services must not exceed the provincial limits, with local prices allowed to be lower [4].